primary dysmenorrhoea. primary dysmenorrhoea
Conditions
Interventions
Intervention 1: intervention group: cholecalciferol 50,000 IU oral tablets, once a week for 8 weeks. Intervention 2: control group: placebo, oral tablet, once a week for 8 weeks.
Treatment - Drugs
Placebo
intervention group: cholecalciferol 50,000 IU oral tablets, once a week for 8 weeks.
control group: placebo, oral tablet, once a week for 8 weeks.
Sponsors
Tehran University of Medical Sciences, Deputy of Research
Eligibility
Sex/Gender
Female
Age
18 Years to 30 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Women aged 18-30 y; with normal menstrual cycles (cycles lasted 21 to 35, with menstrual lasting 3 to 7 days); at least 4 consecutive painful periods in the past 6 months with a diagnosis of primary dysmenorrhea; Serum 25-hydroxyvitamin D level = 30 ng/dl. Exclusion criteria: Secondary menstrual pain diagnosed by ultrasound examination; Previous and current use of intrauterine contraceptive devices within the 6 months prior; Previous and current use of drugs including calcium or vitamin D within the 6 months prior; Recent use of oral contraception drugs during the past 2 months; Smoking; BMI = 30; history of kidney stones; granulomatous disease; hyperparathyroidism and any malignant disease.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Menstrual pain severity. Timepoint: before treatment, 2 months after the treatment, 1 month after finishing intervention. Method of measurement: Visual pain scale. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactShahrzad Jafari-Adli
Tehran University of Medical Sciences (TUMS)
Outcome results
None listed